Metabolic Abnormalities Among Youths Receiving Antipsychotics Across Different Exposure Periods - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Metabolic Changes in Youth Treated With Antipsychotics Over Varying Exposure Durations

  • By

  • Song Song

  • Wenxin Tian

  • Yuqi Hu

  • Cuiling Wei

  • Xinya Mu

  • Rachel Yui Ki Chu

  • Yifang Huang

  • Zijie Xu

  • Heidi Ka Ying Lo

  • Amy Pui Pui Ng

  • Queenie Wing Shan See

  • William Chi Wai Wong

  • Esther Wai Yin Chan

  • Ian Chi Kei Wong

  • Francisco Tsz Tsun Lai

  • October 28, 2026

Share

  • 1

    This first-event self-controlled case series used Hong Kong public health records to assess metabolic abnormalities after antipsychotic initiation in patients aged 6 to 17 years.

  • 2

    Among 15,219 antipsychotic initiators, 497 developed metabolic abnormalities: 115 had hyperglycemia and 447 had dyslipidemia.

  • 3

    Compared with baseline periods, metabolic abnormality incidence was elevated on days 8 to 30 after initiation (IRR, 5.60; 95% CI, 2.93-10.70) and peaked on days 31 to 90 (IRR, 7.71; 95% CI, 5.15-11.55

  • 4

    Incidence remained elevated after 90 days of initial exposure (IRR, 3.94; 95% CI, 2.91-5.33) and during subsequent exposure episodes (IRR, 3.71; 95% CI, 2.51-5.49).

  • 5

    The authors cautioned that increased testing near treatment initiation, delayed detection of preexisting abnormalities, and residual time-varying confounding may have influenced the observed patterns.

Original Source(s)

Metabolic Abnormalities Among Youths Receiving Antipsychotics Across Different Exposure Periods

  • by Song Song, Wenxin Tian, Yuqi Hu, Cuiling Wei, Xinya Mu, Rachel Yui Ki Chu, Yifang Huang, Zijie Xu, Heidi Ka Ying Lo, Amy Pui Pui Ng, Queenie Wing Shan See, William Chi Wai Wong, Esther Wai Yin Chan, Ian Chi Kei Wong, Francisco Tsz Tsun Lai

  • October 28, 2026

Related Content

FDA approves new treatment for FOP

Total new heterotopic ossification volume decreased with treatment and increased with placebo at week 24.

FDA adds generic valganciclovir oral solution

 The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.

CDC recommends 2026–2027 COVID vaccines for all adults

Updated guidance recommends vaccination for adults aged 18 years and older, with pediatric recommendations based on immune status.